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Abstract
Rationale The stress-induced hyperthermia (SIH) model is
an anxiety model that uses the transient rise in body
temperature in response to acute stress. Benzodiazepines
produce anxiolytic as well as sedative side effects through
nonselective binding to GABAA receptor subunits. The
GABAA receptor α1 subunit is associated with sedation,
whereas the GABAA receptor α2 and α3 subunits are
involved in anxiolytic effects.
Objectives We therefore examined the effects of (non)
subunit-selective GABAA receptor agonists on temperature
and locomotor responses to novel cage stress.
Results Using telemetric monitoring of temperature and
locomotor activity, we found that nonsubunit-selective
GABAA receptor agonist diazepam as well as the α3
subunit-selective receptor agonist TP003 dose-dependently
attenuated SIH and locomotor responses. Administration of
GABAA receptor α1-selective agonist zolpidem resulted in
profound hypothermia and locomotor sedation. The
GABAA receptor α1-selective antagonist βCCt antagonized
the hypothermia, but did not reverse the SIH response
attenuation caused by diazepam and zolpidem. These results
suggest an important regulating role for the α1 subunit in
thermoregulation and sedation. Ligands of extrasynaptic
GABAA receptors such as alcohol and nonbenzodiazepine
THIP attenuated the SIH response only at high doses.
Conclusions The present study confirms a putative role for
the GABAA receptor α1 subunit in hypothermia and
sedation and supports a role for α2/3 subunit GABAA
receptor agonists in anxiety processes. In conclusion, we
show that home cage temperature and locomotor responses
to novel home cage stress provide an excellent tool to
assess both anxiolytic and sedative effects of various
(subunit-selective) GABAAergic compounds.
Keywords GABAA receptor subunit . Stress-induced
hyperthermia . Body temperature .βCCt . zolpidem . TP003
Introduction
The involvement of the GABAA receptor in anxiety has
been extensively studied and confirmed (Nemeroff 2003).
The pentameric GABAA receptor consists of five subunits
(α1–6, β1–3, γ1–3, δ, ɛ, θ, and π), and the assembly of
different combinations of subunits allows the construction
of different types of GABAA receptors, each having
specific functional and pharmacological properties (Korpi
et al. 2002). The majority of GABAA receptors are
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composed of two α subunits, two β subunits, and one γ
subunit (Tretter et al. 1997). Classical benzodiazepines bind
to GABAA receptors containing α1, α2, α3, and/or α5
subunits, while binding affinity to α4-containing and α6-
containing subunits is extremely weak (Rudolph and
Mohler 2004). Besides the preferred anxiolytic action, the
use of benzodiazepines is associated with dependence,
anticonvulsant activity, sedation, amnesia, and daytime
drowsiness (Stewart and Westra 2002). These different
benzodiazepine effects are thought to be mediated through
different GABAA receptor subtypes. Therefore, the search
for new anxiolytics focuses on subunit-selective GABAA
receptor agonists. Both genetic and pharmacological studies
suggest a major role of the α2 and the α3 GABAA receptor
subunit in mediating anxiolysis (Atack et al. 2005; Dias et
al. 2005; Low et al. 2000; Rudolph and Mohler 2004).
Consistent with this role, the α2 and the α3 GABAA
receptor subunits are expressed in anxiety-involved areas
like the amygdala and bed nucleus of the stria terminalis
(Pirker et al. 2000). The GABAA receptor α1 subunit is
associated with sedative and amnesic effects, while it is not
involved in anxiolysis (McKernan et al. 2000; Rowlett et al.
2005; Rudolph et al. 1999). Compounds lacking activity at
the α1-containing GABAA receptor while still modulating
the α2 and/or α3 GABAA receptor subunit appear to be
prime candidates for nonsedating anxiolytic drugs (de Haas
et al. 2007; Huang et al. 2000). The research for novel
anxiolytics has focused on compounds with selective
efficacy at different subunits (while binding to all subunits)
rather than compounds with different affinities for the
subunits (Atack 2005). We therefore aimed to characterize
the effects of different GABAA ligands on temperature and
locomotor responses to novel cage stress in rats, using
home cage telemetry, in order to deduce the relative
contributions of α subunits of the GABAA receptor.
Somatic stress symptoms are mediated by the autonomic
nervous system and constitute a functional response in both
humans and animals. The stress-induced hyperthermia (SIH)
paradigm uses the physiological transient rise in body
temperature in response to stress as a new and translational
alternative in anxiety research (Bouwknecht et al. 2007;
Vinkers et al. 2008). Using this paradigm, anxiolytic drugs
including most benzodiazepines have been shown to dose-
dependently attenuate the SIH response (Bouwknecht et al.
2007; Olivier et al. 2002; Van Bogaert et al. 2006). Using
telemetry, stress-induced home cage temperature and loco-
motor activity responses can be simultaneously recorded,
thus facilitating the comparison of effects on body temper-
ature and locomotor activity caused by various GABAergic
drugs. We hypothesized that anxiolytic effects would cause
the SIH response to decrease without influencing basal body
temperature and stress-induced locomotor activity responses.
GABAergic sedative effects on the other hand would be
characterized by a decrease in locomotor activity as well as
general hypothermic state.
In the present study, we investigated the nonsubunit-
selective GABAA receptor agonist diazepam (Pritchett et al.
1989), the intermediate selective α1 subunit GABAA
receptor agonist zolpidem, as well as the selective α3 subunit
GABAA receptor agonist TP003 (Dias et al. 2005).
Zolpidem is approximately fivefold to tenfold more selective
for α1 subunit-containing GABAA receptors than α2 and α3
subunit-containing receptors (Ebert et al. 2006; Petroski et
al. 2006). However, zolpidem may demonstrate less selec-
tivity in vivo compared to studies using recombinant
receptors (Atack et al. 1999). TP003 has lower efficacies at
the different α subtypes with less than 15% potentiation at
the α2 and α5 subunit compared to diazepam (Dias et al.
2005). Exposure to higher drug doses may lead to loss of
selectivity. We combined these compounds with the selective
α1 subunit GABAA receptor antagonist beta-carboline-
carboxy-tert-butyl ester (βCCt; Huang et al. 1999).
Less abundant populations of a δ subunit-containing
GABAA receptors are often located extrasynaptically and
perisynaptically and are thought to be involved in a
continuous active inhibitory tone instead of the phasic
inhibitory tone caused by intrasynaptic agonists (Jia et al.
2005; Nusser et al. 1998). Alcohol is anxiolytic at low doses
and has been shown to bind to extrasynaptic GABAA
receptors containing α4 or α6 and δ subunits (Wallner et al.
2003). However, at higher doses, ethanol can modulate
excitatory N-methyl-D-aspartic acid (NMDA) and non-
NMDA glutamate receptors, serotonin and glycine receptors,
as well as potassium and calcium channels (Crews et al.
1996; Davies 2003; Harris 1999). Also, the fact that δ-
deficient mice demonstrated a normal anxiolytic and
hypothermic response to ethanol and that the alcohol
sensitivity of α4β3δ GABAA receptors could not be
replicated (Borghese et al. 2006) indicates that the discussion
on the mechanism by which ethanol activates the GABAA
receptor is still ongoing (Mihalek et al. 2001). Generally, the
sedative and anxiolytic effects of alcohol were not altered
after deletion of the α1 subunit, suggesting that other yet
unexplained factors may play a role (Kralic et al. 2003).
Moreover, we studied the nonbenzodiazepine hypnotic drug
THIP (gaboxadol) that also binds to extrasynaptic GABAA
receptor δ subunits with putative anxiolytic effects (Elfline et
al. 2004; Wafford and Ebert 2006).
Materials and methods
Animals
Male Wistar rats (Harlan Zeist, The Netherlands) were used
in the current study. Rats were housed socially in a
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controlled environment with a nonreversed 12 h light/dark
cycle (white lights on from 7 AM to 7 PM). Animals had
unlimited access to food (standard laboratory chow) and
water. One week after arrival, telemetry transmitters were
implanted. After recovery from surgery, rats were housed in
groups of four in type IV Macrolon® cages with a plastic
tube as cage enrichment. Food (standard laboratory chow)
and tap water were available ad libitum. Once a week, an
experimental procedure was carried out. All experiments
were carried out with the approval of the ethical committee
on animal experiments of the Faculties of Sciences, Utrecht
University, The Netherlands, and in accordance with the
Declaration of Helsinki.
Surgery
A telemetric device (type ETA-F20, Data Sciences Interna-
tional, St. Paul, MN, USA) was implanted in the abdominal
cavity as described earlier (Pattij et al. 2001). Prior to surgery,
rats received a subcutaneous (s.c.) injection (2 mL/kg) of the
antibiotic Baytrill® (2.5% enrofloxacin). Rats were anesthe-
tized using O2/NO2/isoflurane gas anesthesia. Carprofen
(5 mg/kg, s.c.) was given as an analgesic immediately after
surgery and twice daily for 2 days after surgery. After
surgery, animals were housed individually for 1 week and
recovery from surgery was monitored (weight, heart rate,
temperature). Also, all rats had access to wet food and solid
drinks (gel formula as a water replacement) for 2 days after
surgery. Wound recovery was regularly checked. One animal
repeatedly opened the abdomen wound and, therefore, had to
be sacrificed and replaced. During the experiments, one rat
was removed from the experiments due to an inflammation
surrounding the telemetry device.
Experimental procedure
On the afternoon before an experimental day, rats were
weighed and housed individually in a type III Macrolon®
cage, located on a telemetric receiver. The telemetric
transmitters were activated using a magnet. Data collection
was subsequently started. The day after, the SIH procedure
was initiated, consisting of an injection (intraperitoneal
[i.p.] or oral [p.o.]) with vehicle or a certain drug dose.
Immediately after injection, rats were placed back into their
individual cage. Rats were placed in a novel cage (clean
cage with fresh bedding and a paper tissue) 60 min later
and left undisturbed for approximately 2 h afterwards. At
the end of the experimental day, rats were group-housed
again and transmitters were turned off. To prevent habitu-
ation to the novel cage procedure, the interval between two
experiments was set to be at least 1 week. A within-subject
design was used, and all animals received all (combined)
doses of the drugs.
Drugs
Diazepam, zolpidem, alcohol, and THIP HCl (gaboxadol)
were obtained from Sigma Aldrich. βCCt was synthesized by
the laboratory of Dr. J. M. Cook, University of Wisconsin-
Milwaukee. TP003 was synthesized according to published
methods (Dias et al. 2005; Goodacre et al. 2003; Humphries
et al. 2006). An injection volume of 2 mL/kg was used for
intraperitoneal injections of all drugs, except THIP HCl
(5 mL/kg, i.p.) and alcohol (5 mL/kg p.o.). Diazepam,
zolpidem, βCCt, TP003, and gaboxadol were suspended in
gelatin–mannitol 0.5%/5%. When βCCt was combined with
diazepam or zolpidem, βCCt at a dose of 10 mg/kg was
injected 10 min prior to diazepam/zolpidem injection. Fresh
solutions and suspensions were prepared each testing day.
Data analysis
All data were collected in 5-min blocks and are displayed ±
SEM. All experiments were carried out with a within-subject
design. Body temperature and locomotor activity were ana-
lyzed during the first hour after novel cage using a univariate
repeated-measures analysis of variance (ANOVA) with manip-
ulations time and treatment as within-subject factors. Simple
contrast tests were used to compare drug with vehicle
conditions whenever a significant main effect for drug
(indicating an effect on the basal body temperature) or a
significant drug × time interaction effect (indicating an effect on
the SIH response) was observed. Also, the SIH response was
calculated from the telemetry data for each individual rat by
subtracting the body temperature at t=0 from the maximum
temperature reached within the first 30 min after the novel
cage procedure and compared using a repeated-measures
ANOVA with drug as within-subject factor and simple
contrasts to compare drug with vehicle conditions. In addition,
cumulative locomotor activity after the first 60 min after
injection and cumulative locomotor activity after the first
60 min after the novel cage procedure were calculated and
compared using repeated-measures ANOVA. A probability
level of p<0.05 was set as statistically significant; probability




Diazepam dose-dependently attenuated the SIH response to
novel cage stress without affecting basal body temperature
and reduced locomotor activity levels before and after the
novel cage procedure only at higher doses (Fig. 1a, c; n=11).
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Body temperature
The novel cage SIH response (F(12,120)=22.0, p<0.001)
was reduced by diazepam (diazepam × time interaction: F
(36,360)=4.31, p<0.001). Diazepam did not influence basal
body temperature (diazepam effect: F(3,30)=1.04, p=0.39,
NS) (Fig. 1a). The calculated SIH response revealed a
diazepam effect on the SIH response (F(3,30)=12.74, p<
0.001). Simple contrasts revealed SIH attenuation at higher
doses (1 mg/kg–vehicle: F(1,10)=3.85, p=0.08, trend; 2 mg/
kg–vehicle: F(1,10)=6.03, p<0.05; 4 mg/kg–vehicle: F
(1,10)=33.51, p<0.001) (Fig. 1a, inset).
Fig. 1 The effects of diazepam with and without βCCt on the novel
cage-induced temperature and locomotor responses (t=−60 injection, t=
0 novel cage stress). *p<0.05; **p<0.01; ***p<0.001. Inset calculated
SIH response from the telemetry data. a Diazepam (0–4 mg/kg) dose-
dependently reduced the SIH response. Inset calculated SIH response
from the telemetry data. b Diazepam at a dose of 4 mg/kg reduced core
body temperature and the SIH response. Prior injection with βCCt
(10 mg/kg) prevented basal core body temperature reduction without
affecting the diazepam-induced reduction of the SIH response *p<0.05,
diazepam effect and diazepam × βCCt interaction. Inset calculated SIH
response from the telemetry data. c Diazepam (4 mg/kg) reduced stress-
induced locomotor activity responses [Inset white bar cumulative
locomotor activity t=−60 to t=0 (after injection), gray bar cumulative
locomotor activity t=0 to t=60 (after novel cage)]. d Diazepam (4 mg/
kg) reduced stress-induced locomotor activity responses with no effect
of βCCt [Inset white bar cumulative locomotor activity t=−60 to t=0
(after injection), gray bar cumulative locomotor activity t=0 to t=60
(after novel cage)]. e βCCt (0–20 mg/kg) did not affect SIH responses
Inset calculated SIH response from the telemetry data
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Locomotor activity
The novel cage stress-induced locomotor activity response (F
(12,120)=20.55, p<0.001) was overall diminished by diaze-
pam (diazepam effect: F(3,30)=4.98, p<0.01), although not
dependent upon time (diazepam × time interaction: F(3,30)=
1.33, p=0.11, NS). Only the higher doses of diazepam
influenced locomotor activity [planned comparisons: vehicle–
1 mg/kg (F(1,10)=1.68, p=0.22, NS), vehicle–2 mg/kg (F
(1,10)=8.18, p<0.05), and vehicle–4 mg/kg (F(1,10)=7.03,
p<0.05)]. When cumulating locomotor activity levels after
injection and after stress (Fig. 1c, inset), diazepam reduced
locomotor activity levels at higher doses (main diazepam
effect: F(3,30)=3.03, p<0.05; simple contrasts: 2 mg/kg vs
vehicle F(1,10)=3.85, p=0.08, NS; 4 mg/kg vs vehicle F
(1,10)=5.19, p<0.05). Activity levels were larger after the




βCCt alone did not affect the SIH response (time effect: F
(12,120)=53.00, p<0.001; βCCt effect: F(3,30)=0.70, p=
0.56, NS; βCCt × time interaction: F(36,360)=1.17, p=
0.24, NS) (Fig. 1e; n=11).
The calculated SIH response revealed no βCCt effect on
the SIH response (F(3,30)=0.33, p=0.80, NS). Simple
contrasts revealed that there was no attenuation of the SIH
response at any dose (3 mg/kg–vehicle: F(1,10)=0.06, p=
0.83, NS; 10 mg/kg–vehicle: F(1,10)=0.29, p=0.61, NS;
20 mg/kg–vehicle: F(1,10)=0.13, p=0.72, NS) (Fig. 1e,
inset).
Locomotor activity
βCCt did not influence the stress-induced locomotor
activity responses (time effect: F(12,120)=13.72, p<
0.001; βCCt effect: F(3,30)=0.23, p=0.88, NS; βCCt ×




βCCt was able to partially reverse the diazepam-induced
hypothermia without affecting diazepam’s ability to
reduce the SIH response. βCCt was not able to reverse
the diazepam-induced locomotor reduction (Fig. 1b, d;
n=8).
Body temperature
When combined with βCCt, the SIH response (time effect:
F(12,84)=9.85, p<0.001) was overall reduced by diazepam
(diazepam × time interaction: F(12,84)=5.17, p<0.001).
βCCt did not influence the SIH response (βCCt × time
interaction: F(12,84)=1.38, p=0.19, NS). Diazepam re-
duced basal body temperature (diazepam effect: F(1,7)=
6.96, p<0.05) and βCCt influenced the diazepam-induced
hypothermia (diazepam × βCCt interaction: F(1,7)=6.18, p
<0.05) without altering the body temperature itself (βCCt
effect: F(1,7)=1.24, p=0.30, NS). The calculated SIH
response revealed that diazepam reduced the SIH response
(diazepam effect: F(1,7)=16.94, p<0.01). βCCt itself did
not affect the SIH response (βCCt effect: F(1,7)=1.86, p=
0.22, NS) nor did βCCt affect the attenuation of the SIH
response by diazepam (diazepam×βCCt interaction: F(1,7)=
0.68, p=0.44, NS) (Fig. 1b, inset).
Locomotor activity
When diazepam was injected after βCCt, the stress-induced
locomotor activity response (time effect: F(12,84)=7.65, p
<0.001) was generally and time-dependently reduced by
diazepam (diazepam effect: F(1,7)=9.48, p<0.05; diaze-
pam×time interaction: F(12,84)=3.45, p<0.001) with no
effect of βCCt (βCCt effect: F(1,7)=0.20, p=0.68, NS;
βCCt×time interaction: F(12,84)=0.32, p=98, NS; βCCt ×
diazepam interaction: F(1,7)=0.02, p=0.88, NS). When
cumulating locomotor activity levels after injection and
after stress (Fig. 1d, inset), diazepam generally reduced
locomotor activity levels (main diazepam effect: F(1,7)=
10.86, p=0.01; stress effect: F(1,7)=2.47, p=0.16, NS)
without effect of βCCt (βCCt effect: F(1,7)=0.05, p=0.82,




Zolpidem dose-dependently reduced basal body tempera-
ture and the SIH response and attenuated stress-induced and
basal locomotor activity levels (Fig. 2a, c; n=12).
Body temperature
Zolpidem reduced basal body temperature (main zolpidem
effect: F(3,33)=9.85, p<0.001). Basal body temperature was
found to be reduced in all three dosages [planned compar-
isons: vehicle–3 mg/kg (F(1,11)=8.89, p<0.05), vehicle–
10 mg/kg (F(1,11)=27.98, p<0.001), and vehicle–30 mg/kg
(F(1,11)=26.73, p<0.001)]. The SIH response (time effect:
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F(12,132)=15.70, p<0.001) was reduced by zolpidem
(zolpidem × time interaction: F(36,396)=10.12, p<0.001).
The calculated SIH response revealed that zolpidem reduced
the SIH response (F(3,33)=12.71, p<0.001). Simple con-
trasts revealed SIH attenuation at all doses (3 mg/kg–vehicle:
F(1,11)=18.17, p<0.001; 10 mg/kg–vehicle: F(1,11)=
100.61, p<0.001; 30 mg/kg–vehicle: F(1,11)=24.10, p<
0.001) (Fig. 2a, inset).
Locomotor activity
The stress-induced locomotor response (main time effect: F
(12,132)=12.48, p<0.001) was reduced by zolpidem (main
zolpidem effect: F(3,33)=7.41, p<0.001; zolpidem × time
interaction: F(36,396)=1.98, p<0.001). Locomotor activity
was found to be reduced in all three dosages [planned
comparisons: vehicle–3 mg/kg (F(1,11)=8.27, p<0.05),
vehicle–10 mg/kg (F(1,11)=12.25, p<0.01), and vehicle–
30 mg/kg (F(1,11)=13.34, p<0.01)]. When cumulating
locomotor activity levels after injection and after novel cage
stress (Fig. 2c, inset), zolpidem was found to reduce overall
locomotor activity (main zolpidem effect: F(3,33)=12.21,
p<0.001; zolpidem × stress interaction: F(3,33)=0.31, p=
0.69, NS). Simple contrasts showed that all doses of
zolpidem reduced cumulative locomotor activity (vehicle–
3 mg/kg: F(1,11)=12.28, p<0.01; vehicle–10 mg/kg: F
(1,11)=12.37, p<0.01; vehicle–30 mg/kg: F(1,11)=25.11,
p<0.001). Novel cage-induced locomotor levels were larger




βCCtwas able to partially reverse the overall zolpidem-induced
hypothermia as well as time-dependently partially reverse the
zolpidem-induced locomotor sedation (Fig. 2b, d; n=8).
Fig. 2 The effects of zolpidemwith and withoutβCCt on the novel cage-
induced temperature and locomotor responses (t=−60 injection, t=0
novel cage stress). *p<0.05; **p<0.01; ***p<0.001. a Zolpidem (0–
30 mg/kg) dose-dependently reduced the SIH response and basal body
temperature. Inset calculated SIH response from the telemetry data. b
Zolpidem at a dose of 10 mg/kg reduced core body temperature and the
SIH response. Prior injection with βCCt (10 mg/kg) reversed basal core
body temperature reduction without affecting the zolpidem-induced
reduction of the SIH response. **p<0.01, zolpidem effect; *p<0.05,
zolpidem × βCCt interaction. Inset calculated SIH response from the
telemetry data. c Zolpidem (0–30 mg/kg) dose-dependently reduced
stress-induced locomotor activity responses. Inset: white bar cumulative
locomotor activity t=−60 to t=0 (after injection), gray bar cumulative
locomotor activity t=0 to t=60 (after novel cage). d Zolpidem (10 mg/
kg) reduced stress-induced locomotor activity responses. βCCt partially
reversed zolpidem-induced locomotor sedation. *p<0.05, zolpidem ×
βCCt interaction. Inset: white bar cumulative locomotor activity t=−60
to t=0 (after injection), gray bar cumulative locomotor activity t=0 to t=
60 (after novel cage)
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Body temperature
When combined with βCCt, zolpidem did not significantly
reduce the SIH response (main time effect: F(12,84)=9.75,
p<0.001; zolpidem × time interaction: F(12,84)=0.93, p=
0.54, NS). Also, βCCt did not influence the SIH response
(βCCt × time interaction: F(12,84)=0.92, p=0.53, NS).
Zolpidem reduced basal body temperature (main zolpidem
effect: F(1,7)=11.12, p<0.01), and βCCt influenced the
zolpidem-induced hypothermia (zolpidem × βCCt interac-
tion: F(1,7)=6.31, p<0.05) without altering the body
temperature itself (βCCt effect: F(1,7)=2.54, p=0.16,
NS). The calculated SIH response revealed that zolpidem
reduced the SIH response (diazepam effect: F(1,7)=11.31,
p=0.01). βCCt itself did not affect the SIH response (βCCt
effect: F(1,7)=0.01, p=0.97, NS) nor did βCCt affect the
attenuation of the SIH response by zolpidem (zolpidem×βCCt
interaction: F(1,7)=0.25, p=0.63, NS) (Fig. 2b, inset).
Locomotor activity
When combined with βCCt, zolpidem overall reduced
locomotor responses (main zolpidem effect: F(1,7)=7.80,
p<0.05; zolpidem × time interaction: F(1,7)=1.99, p<
0.05). βCCt had no overall effect on locomotor responses
(βCCt effect: F(1,7)=1.94, p=0.21, NS). However, βCCt
reversed locomotor activity in the zolpidem group depen-
dent upon time (zolpidem × βCCt × time interaction: F
(12,84)=1.91, p<0.05; zolpidem × βCCt interaction: F
(1,7)=0.18, p=0.69, NS). When cumulating locomotor
activity levels after injection and after novel cage stress
(Fig. 2d, inset), zolpidem reduced basal and stress-induced
locomotor activity (zolpidem effect: F(1,7)=16.73, p<
0.01; stress effect: F(1,7)=1.61, p=0.25, NS) without
overall effect of βCCt (βCCt effect: F(1,7)=2.09, p=




TP003 reduced the SIH response at higher doses as well as
reduced basal body temperature and attenuated novel cage-
induced activity more than injection-induced activity
(Fig. 3a, b; n=10).
Body temperature
The SIH response (main time effect: F(12,108)=19.27, p<
0.001) was attenuated by TP003 (TP003×time interaction:
F(36,324)=1.93, p<0.01). TP003 did influence basal core
body temperature (F(3,27)=2.96, p=0.050). Planned com-
parisons revealed a significant difference between the
vehicle and 1 mg/kg condition (F(1,9)=6.26, p<0.05), a
trend for a difference between vehicle and 3 mg/kg
condition (F(1,9)=3.65, p=0.09, NS), and no difference
between vehicle and 0.3 mg/kg condition (F(1,9)=0.27, p=
0.62,NS). The calculated SIH response revealed TP003
reduced the SIH response (F(3,27)=12.57, p<0.001).
Simple contrasts revealed SIH attenuation at all doses
(0.3 mg/kg–vehicle: F(1,9)=22.25, p<0.001; 1 mg/kg–
vehicle: F(1,9)=25.50, p<0.001; 3 mg/kg–vehicle: F(1,9)=
27.79, p<0.001) (Fig. 3a, inset).
Locomotor activity
Stress-induced locomotor responses (main time effect: F
(12,108)=22.43, p<0.001) were reduced by TP003 (TP003
effect: F(3,27)=14.43, p<0.001; TP003×time interaction:
F(36,324)=1.42, p=0.06). All three TP003 doses resulted in
significant activity reduction after novel cage stress com-
pared to the vehicle group (F(1,9)=23.94, p<0.001 for
vehicle–0.3 mg/kg, F(1,9)=25.56, p<0.001 for vehicle–
1 mg/kg, and F(1,9)=14.09, p<0.01 for vehicle–3 mg/kg,
simple contrasts). When cumulating locomotor activity
levels after injection and after novel cage stress (Fig. 3b,
inset), TP003 reduced locomotor activity levels after novel
cage stress more than after injection (TP003 effect: F(3,27)=
9.34, p<0.001; TP003×pre–post interaction: F(1,9)=9.81,
p<0.001), Although activity levels were comparable after




Alcohol reduced the SIH response and basal body temper-
ature only at higher doses. Alcohol did not affect locomotor
activity levels after injection and after novel cage stress
(Fig. 3c, d; n=11).
Body temperature
Novel cage stress led to a significant increase in temperature
(time effect: F(12,120)=15.68, p<0.001) and alcohol re-
duced the SIH response (time × alcohol interaction: F
(36,360)=2.56, p<0.001). Alcohol decreased basal body
temperature (main alcohol effect: F(3,30)=4.82, p<0.01).
Simple contrasts revealed differences only between vehicle
and 3 g/kg regarding basal body temperature (dose contrasts:
vehicle–0.3 g/kg: F(1,10)=0.79, NS; vehicle–1 g/kg: F
(1,10)=0.01, p=0.98, NS; vehicle–3 g/kg: F(1,10)=5.71,
p<0.05). The calculated SIH response showed a trend for
alcohol to reduce the SIH response (F(3,30)=2.30, p=0.09,
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Fig. 3 The effects of TP003 (0–3 mg/kg, a and b), alcohol (0–3 g/kg,
c and d), and THIP (0–10 mg/kg, e and f) on the novel cage-induced
temperature and locomotor responses (t=−60 injection, t=0 novel
cage stress). *p<0.05; **p<0.01; ***p<0.001. a TP003 reduced the
SIH response at higher doses. Inset: calculated SIH response from the
telemetry data. b TP003 dose-dependently reduced stress-induced
locomotor activity responses (***). Inset graphs: white bar cumula-
tive locomotor activity t=−60 to t=0 (after injection stress), gray bar
cumulative locomotor activity t=0 to t=60 (after novel cage stress).
[TP003 reduced overall locomotor activity (TP003 effect: *p<0.001),
but more so after the novel cage procedure (TP003×stress effect, *p<
0.001)]. c Alcohol at the highest dose reduced the SIH response (***)
and basal body temperature (**). Inset calculated SIH response from
the telemetry data. d Alcohol did not affect stress-induced locomotor
activity responses. Inset graphs: white bar cumulative locomotor
activity t=−60 to t=0 (after injection stress), gray bar cumulative
locomotor activity t=0 to t=60 (after novel cage stress). e THIP at the
highest dose reduced the SIH response (***) and basal body
temperature (**). Inset: calculated SIH response the telemetry data. f
THIP at the highest dose reduced stress-induced locomotor activity
responses. Inset THIP did not reduce overall locomotor activity, but
did reduce locomotor activity after the novel cage procedure
(gaboxadol × stress effect, ***p<0.05)
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NS). Simple contrasts revealed SIH attenuation at higher
doses (1 g/kg–vehicle: F(1,10)=1.32, p=0.28, NS; 2 g/kg–
vehicle: F(1,10)=5.19, p<0.05; 4 g/kg–vehicle: F(1,10)=
5.12, p<0.05) (Fig. 3c, inset).
Locomotor activity
The locomotor reaction in response to novel cage stress
(time effect: F(12,120)=16.87, p<0.001) was not affected
by alcohol (main alcohol effect: F(3,30)=0.62, p=0.61,
NS; alcohol×time interaction: F(36,360)=1.23, p=0.18,
NS). When cumulating locomotor activity levels after
injection and after novel cage stress (Fig. 3d, inset), alcohol
did not affect locomotor activity levels after injection and
after novel cage stress (alcohol effect: F(3,30)=1.67, p=
0.20, NS; alcohol × stress: F(3,30)=0.90, p=0.45, NS).
THIP
Summary
THIP reduced the SIH response and basal body temperature
at its highest dose. THIP reduced locomotor activity after
novel cage stress (Fig. 3e, f; n=10).
Body temperature
Basal body temperature was overall reduced by THIP
(THIP effect: F(3,27)=5.44, p<0.01). Also, the SIH
response (time effect: F(12,108)=12.59, p<0.001) was
reduced by THIP (THIP × time interaction: F(36,324)=
4.25, p<0.001). Simple contrasts revealed a significant
difference in basal body temperature between the vehicle
and 10 mg/kg condition (F(1,9)=15.40, p<0.01), whereas
the other doses did not affect basal body temperature
(vehicle–0.3 mg/kg condition F(1,9)=1.11, p=0.32, NS;
vehicle–3 mg/kg condition F(1,9)=0.11, p=0.75, NS). The
calculated SIH response revealed that THIP reduced the
SIH response (F(3,27)=4.64, p=0.01). Simple contrasts
revealed that only the highest dose reduced the SIH
response (0.3 mg/kg–vehicle: F(1,9)=0.31, p=0.59, NS;
3 mg/kg–vehicle: F(1,9)=0.25, p=0.63; 10 mg/kg–vehicle:
F(1,10)=6.15, p<0.05) (Fig. 3e, inset).
Locomotor activity
The stress-induced locomotor response (time effect: F
(12,108)=12.35, p<0.001) was reduced by THIP (THIP ×
time interaction: F(36,324)=1.96, p<0.001; THIP effect: F
(3,27)=2.43, p=0.09, trend). When cumulating locomotor
activity levels after injection and after novel cage stress
(Fig. 3f, inset), THIP reduced locomotor activity levels only
after the novel cage procedure (THIP × stress interaction: F
(1,9)=3.37, p<0.05), although overall locomotor activity
was not reduced (THIP effect: F(3,27)=1.18, p=0.34, NS)
and overall locomotor activity levels after injection and
novel cage stress were not different (stress effect: F(1,9)=
0.18, p=0.68, NS).
Discussion
In the present study, we examined the effects of various
GABAAergic compounds on temperature and locomotor
responses to acute stress. The SIH model uses the rise in
body temperature in response to stress to assess anxiolytic
drug effects and provides a translational approach to
anxiety research (Vinkers et al. 2008). We found that the
administration of the nonselective GABAA receptor agonist
diazepam resulted in a dose-dependent attenuation of the
SIH and basal and stress-induced locomotor activity
responses, indicating that diazepam induces both anxiolytic
and sedative effects. These findings support and extend
previous studies on diazepam in the SIH paradigm in mice
(Olivier et al. 2002). Zolpidem, an intermediate selective
GABAA receptor α1 subunit agonist, decreased basal core
body temperature and attenuated basal and stress-induced
locomotor and temperature responses in a dose-dependent
fashion. The sedative effect of zolpidem in vivo is mediated
by the α1 subunit (Crestani et al. 2000), and zolpidem does
not possess any anxiolytic properties (Kralic et al. 2002;
Mathiasen et al. 2007). However, we cannot exclude that
the results of the higher doses of zolpidem may be the result
of nonspecific GABAA receptor activation. Also, the
reduction of the SIH response by zolpidem is most likely
the result of strong hypothermic effects on basal body
temperature, disturbing physiological homeostatic mecha-
nisms (Olivier et al. 2003).
βCCt shows a high affinity for the GABAA receptor α1
subunit with considerably lower affinity for GABAA
receptor α2, α3, and α4 subunits and has comparable low
efficacy at all α subunits. (Basile et al. 2006; Huang et al.
2000). Administration of βCCt alone had no effect on
either basal body temperature or novel cage-induced
temperature and locomotor activity responses. However,
prior injection with βCCt antagonized hypothermic effects
of both diazepam and zolpidem and reversed zolpidem-
induced locomotor sedation (Figs. 1 and 2). In contrast,
βCCt did not antagonize the diazepam-induced locomotor
sedation, which may be attributed to the fact that diazepam
exerts a broader pharmacological GABAA agonistic profile
while zolpidem action is restricted to the GABAA receptor
α1 subunit. Basal body temperature reduction after diaze-
pam administration was only observed in the combination
βCCt/diazepam experiment and not when solely diazepam
was injected. We do not have an explanation for this
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puzzling observation; the only experimental difference was
the presence of a double injection within 10 min. Mice do
consistently show a reduction in basal body temperature
after administration of diazepam (Olivier et al. 2002; Van
Bogaert et al. 2006), and better regulated homeostasis in the
rat may account for an absent hypothermia when diazepam
was administered. Our results suggest a role for the
GABAA receptor α1 subunit in hypothermic and locomotor
sedative actions of GABAAergic drugs. Some studies have
suggested that anxiolytic effects of benzodiazepines can be
reversed with βCCt (Belzung et al. 2000; Griebel et al.
1999). However, this may be the result of decreased
sedation rather than a reversal of anxiolytic effects, since
sedation caused by diazepam and zolpidem has been shown
to be reversible with high doses of βCCt (Basile et al.
2006; Griebel et al. 1999). The hypothermic effects after
activation of the GABAA receptor α1 subunit has been
extensively studied in mice (Van Bogaert et al. 2006). The
α1 subunit is abundantly expressed throughout the brain,
and a higher expression of the α1 subunit is present in the
hypothalamic preoptic area and dorsomedial hypothalamus
compared to the α2 and α3 subunits (Pirker et al. 2000).
These areas are thought to play a major role in thermoreg-
ulation (Boulant 2000; Dimicco and Zaretsky 2007;
Nagashima et al. 2000) and may account for the α1
involvement in the regulation of basal body temperature.
A putative role for the GABAA receptor α3 subunit in
anxiety was confirmed with GABAA receptor α3 subunit
agonist TP003 that attenuated the SIH response without
affecting basal body temperature levels (Fig. 3a). Also,
when combined with GABAA receptor α1 subunit antago-
nist βCCt, diazepam still reduced the SIH response,
putatively through activation of the α2/3 subunit. Although
transgenic mice lacking benzodiazepine sensitivity in the
α3 subunit did not show altered anxiolytic actions of
diazepam (Low et al. 2000; Rudolph and Mohler 2004),
pharmacological studies have pointed to a role for this
subunit in anxiolysis (Atack et al. 2005; Atack et al. 2006;
Dias et al. 2005) as might be expected from high α3 subunit
expression in brain areas involved in acute stress responses
(Pirker et al. 2000). Anxiolytic effects of TP003 were found
in the elevated plus maze (rats) and in a conditioned
emotional response test (squirrel monkeys) (Dias et al.
2005). Our findings support and extend previous experi-
ments suggesting GABAA receptor α2 and α3 subunits as
the main regulatory subunits mediating anxiolytic effects
(Atack et al. 2005; Dias et al. 2005). Stress-induced
locomotor responses after novel cage stress were reduced
at all TP003 doses, but only after novel cage stress and not
immediately after injection like in the case of diazepam and
zolpidem (Fig. 3b). This contrasts with another study in
mice that did not show any sedative locomotor effects of
TP003 (Dias et al. 2005). Although being α3 subunit-
selective, TP003 also has low modulation via α1-, α2-, and
α5-containing subtypes (Dias et al. 2005). Also, differences
in metabolizing enzymes exist between animal species,
resulting in different clearance rates which are frequently
thought to be responsible for differences in behavioral
responses. For GABAA receptor agonists, one study of
nitrazepam found much higher plasma levels in rats than in
mice after a dose of nitrazepam (Takeno et al. 1993),
whereas another study found that the oral bioavailability of
L-838417, a α1 subunit antagonist and α2/α3 partial subunit
agonist, in mice was very poor compared to bioavailability
in rats (Scott-Stevens et al. 2005). Therefore, a lack of
sedative action of TP003 in mice compared to rats can
possibly be ascribed to lower plasma levels of TP003
caused by a more rapid metabolism of TP003 in mice.
Locomotor activity responses to stress are used as an
output parameter in various anxiety paradigms such as the
elevated plus maze, the open field test, and the light/dark
test. Open-arm entries, a lit box, or center of a field all
putatively lead to an anxiety state, but also cage exchange
as used in the current experiments leads to similar increases
in distances traveled and velocities (de Visser et al. 2006).
In general, stress-induced behavior in rodents consists of
exploration on one hand and anxiety-driven avoidance
behavior on the other hand, and there is no easy way of
establishing the relationship between exploration and
anxiety. Anxiolytic drugs increase explorative behavior
and locomotor activity (Belzung and Berton 1997), but in
higher doses cause general locomotor sedation, interfering
with a good test interpretation (Dawson et al. 1995).
Therefore, sedative effects of both diazepam and zolpidem
cause a decrease in locomotor activity (Davies et al. 1994;
Elliot and White 2001). However, the sedative effects of
benzodiazepines in the elevated plus maze are no longer
present after a point mutation of the α1 subunit (McKernan
et al. 2000; Rudolph et al. 1999), indicating that the α1
subunit is closely involved in benzodiazepine-induced
locomotor activity reduction. McKernan et al. showed that
diazepam (3 mg/kg) even increased locomotor activity in
α1 subunit point-mutated mice compared to wild-type
controls. In contrast, myorelaxant effects of diazepam in
the rotarod assay remain present in the α1 subunit KO mice,
suggesting that the locomotor activity attenuation is not the
mere result of muscle relaxation. Other studies showed that
βCCt antagonized the locomotor depressant effects of
zolpidem and diazepam on open field locomotor activity in
mice (Griebel et al. 1999) as well as the elevated plus maze
(Savic et al. 2004). All in all, there is ample evidence that
locomotor depressant actions of zolpidem and the benzodia-
zepines are mediated via the α1 subunit of the GABAA
receptor. Anxiolytic drugs completely devoid of sedative side
effects would, therefore, either increase or not affect
locomotor activity parameters after novelty-induced stress.
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Alcohol reduced basal body temperature at higher doses
without affecting stress-induced locomotor responses
(Fig. 3c). Only the highest dose reduced the SIH response,
an effect that was already earlier observed in mice (Olivier
et al. 2003). Although acute administration of alcohol is
known to possess an anxiolytic profile, the effects are
known to be different from benzodiazepines (Langen et al.
2002) as alcohol binds to extrasynaptic GABAA receptors
containing α4 or α6 and δ subunits (Wallner et al. 2003).
However, we used higher doses that could have lost
extrasynaptic binding selectivity. Also, alcohol at higher
doses may act on NMDA, serotonin, and glycine receptors
(Crews et al. 1996; Davies 2003; Harris 1999). THIP
reduced basal body temperature and SIH and locomotor
activity responses only at the highest dose tested (10 mg/
kg), whereas lower doses did not have any effect (Fig. 3e).
THIP has been shown to enhance sleep episodes (Lancel
and Langebartels 2000) with little affinity for benzodiaze-
pine receptors. Rather, THIP binds to extrasynaptic
GABAA receptors containing a δ subunit (Wafford and
Ebert 2006), and a role for the GABAA receptor δ subunit
in neurosteroid-mediated anxiolytic effects has been pro-
posed (Mihalek et al. 1999). However, it seems more likely
that the strong hypothermic effects of the highest dose of
THIP are due to interference with physiological thermo-
regulation (Olivier et al. 2003). Interaction between effects
on sleep and thermoregulation are possible because of
common neural pathways within the preoptic area and
anterior hypothalamus (Frosini et al. 2004). Indeed, THIP
synchronized hypothermic and EEG effects in rabbits
(Frosini et al. 2004). Interestingly, alcohol did not affect
locomotor activity at all doses and THIP affected locomotor
activity only at high doses (Fig. 3d, f), whereas the other
synaptic compounds all reduced locomotor activity to some
extent. Other studies have found that alcohol impaired
rotarod performance at lower doses (Zaleski et al. 2001).
Although our high doses may have lost extrasynaptic
selectivity, this indicates that locomotor activity may be
differentially controlled by extrasynaptic and synaptic
receptor populations. This is supported by a lack of cross-
tolerance in the rotarod test between zolpidem and THIP
(Voss et al. 2003).
The SIH amplitude decreased over the course of the
experiments from 0.7°C at the start of the experiments to
0.2–0.3°C in the final experiments, as did locomotor
activity levels after novel cage stress. Habituation to the
experimental procedure may account for a decreased SIH
response, although previous methodological testing has not
revealed any habituation using a 1-week interval, even
when testing occurred for over a year (Bouwknecht et al.
2007; Olivier et al. 2003; Van der Heyden et al. 1997).
Also, the manually calculated SIH response from the time
graphs is generally in complete agreement with the time
graphs. Only when drugs are tested at doses that markedly
decrease body temperature, there appears to be a small
difference between the calculated SIH response and the
time graphs. This difference is attributable to the fact that
the calculated SIH response is based on the maximum
temperature during the first 30 min after stress. In those
cases in which body temperature is decreasing after stress
induction, the maximum is likely to be close to the start of
that 30-min period. In this way, the calculated SIH response
in these cases is likely to yield a result close to 0°C,
whereas a decreasing basal body temperature seems to
indicate a negative SIH response. The differences, however,
are small and do not change the interpretation of our data.
The most important finding in the present study is that
the GABAA receptor modulates temperature and locomotor
stress responses as well as basal body temperature
processes through different GABAA receptor subunits.
More specifically, the GABAA α1 receptor subunit was
found to be essential for basal body temperature regulation
and for inducing locomotor sedation, whereas the GABAA
receptor α2 and α3 subunit exerted anxiolytic effects by
attenuating the SIH response. Nonbenzodiazepine GABAA
activity is less involved in thermoregulation and locomotor
sedation, as suggested by the effects of alcohol and THIP.
In conclusion, we show that the use of home cage
temperature and locomotor stress responses provides a
successful approach to anxiety research and possesses an
enormous potential to pharmacologically study the effects
of GABAAergic drugs. The SIH model uses a simulta-
neously collected independent parameter and may possess
additional value over locomotor activity parameters only.
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